METHODS OF PRODUCING COMPOSITIONS WITH IMPROVED SAFETY PROFILE CONTAINING PANCREATIN, AND COMPOSITIONS SUITABLE FOR PHARMACEUTICAL USE Russian patent published in 2020 - IPC A61K9/20 A61K9/16 A61K38/18 A61K47/44 A61K47/34 A61P1/18 

Abstract RU 2712142 C2

FIELD: medicine; pharmaceuticals.

SUBSTANCE: group of inventions relates to the pharmaceutical industry, specifically to a method of producing a solid and a semi-solid composition. Method of producing a solid or semi-solid composition comprising a step of treating a mixture comprising pancreatin and/or a mixture of digestive enzymes obtained from a mammal, a surface-active component, antioxidant, polymer additives selected from hydrophilic polymers with melting points or glass transition temperatures of 50–160 °C, wherein weight of components in amount of 100 wt. %; ratio of polymer additive to surface-active component ranges from 0.4 (2:5) to 1.5 (3:2); mixture is treated by molding from melt at temperature of 90–130 °C for a period of time from 30 s to 45 min. Solid or semi-solid composition for preventing or treating diseases selected from digestive disorders, pancreatic exocrine insufficiency, pancreatitis, mucoviscidosis, type I and/or type II diabetes. Pharmaceutical composition for preventing or treating diseases selected from digestive disorders, pancreatic exocrine insufficiency, pancreatitis, mucoviscidosis, type I diabetes and/or type II diabetes. Solid or semi-solid composition or pharmaceutical composition for preventing or treating diseases selected from digestive disorders, pancreas exocrine insufficiency, pancreatitis, mucoviscidosis, type I and/or type II diabetes.

EFFECT: method described above enables to reduce undesirable contamination of the composition while maintaining enzymatic activity.

22 cl, 2 dwg, 19 tbl, 60 ex

Similar patents RU2712142C2

Title Year Author Number
COMPOSITION AND DOSAGE FORM CONTAINING SOLID OR SEMISOLID MATRIX 2006
  • Rozenberg Jorg
  • Mehgerljajn Markus
  • Brajtenbakh Jorg
RU2423997C9
PHARMACEUTICALLY ACCEPTABLE SOLUBILISING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING IT 2007
  • Rozenberg Jorg
  • Brajtenbakh Jorg
  • Marsh Kennan
  • Lipol'D Bernd
  • Shmidt Kristof
  • Lander Ute
RU2469708C2
COMPOSITION CONTAINING FENOFIBRIC ACID OR PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND CAPSULE CONTAINING COMPOSITION 2008
  • Rozenberg Jorg
  • Degenkhardt Matias
  • Brajtenbakh Jorg
  • Rejlehnd Tom L.
  • Marsh Kennehn K.
RU2500398C2
PHARMACEUTICAL DOSED FORM FOR PERORAL INTRODUCTION OF BCL-2 FAMILY INHIBITOR 2010
  • Pakkhojzer Klaudia
  • Shtajger Norbert
  • Lipol'D Bernd
  • Kostelak Dratsen
  • Knoblokh Martin
RU2568599C2
ANTI-RETROVIRAL COMBINATION 2014
  • Lulla Amar
  • Malkhotra Dzhina
RU2675831C2
METHOD AND DEVICE FOR PRODUCTION OF SOLID DISPERSION 2018
  • Adage, Tiziana
RU2785565C2
PHARMACEUTICAL COMPOSITION FOR HIV INFECTION TREATMENT 2016
  • Khazanova Elena Sergeevna
  • Nogaj Sergej Yurevich
  • Yakovlev Dmitrij Vladimirovich
RU2619840C1
PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION 2007
  • Lipol'D Bernd
  • Rozenberg Jorg
  • Knoblokh Martin
  • Nehen Kristian
RU2468788C2
COMPOSITION CONTAINING PHENOFIBRIN ACID, ITS PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE 2003
  • Rozenberg Jorg
  • Degenkhardt Matias
  • Brajtenbakh Jorg
  • Rejlehnd Tom L.
  • Marsh Kennehn K.
RU2356549C2
PHARMACEUTICAL DOSED FORM, CONTAINING POLYMER CARRIER COMPOSITION 2009
  • Lipol'D Bernd
  • Brajtenbakh Jorg
  • Megerljajn Markus
  • Pakkhojzer Klaudija
  • Kessler Tomas
RU2519679C9

RU 2 712 142 C2

Authors

Shliut Georg

Brajtenbakh Jorg

Rupp Kristofer

Ryuffer Frauke-Regina

Shchesny Fritof

Dates

2020-01-24Published

2015-11-05Filed